

STARR CHRISTOPHER M
Form 4
April 04, 2012

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
STARR CHRISTOPHER M

(Last) (First) (Middle)

C/O RAPTOR
PHARMACEUTICAL CORP., 9
COMMERCIAL BLVD., SUITE 200

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Raptor Pharmaceutical Corp [RPTP]

3. Date of Earliest Transaction
(Month/Day/Year)
04/02/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
Chief Executive Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	04/02/2012 ⁽¹⁾		M		10,085 A \$ 2.83	1,092,758	D
Common Stock	04/02/2012 ⁽¹⁾		S		300 D \$ 6.66	1,092,458	D
Common Stock	04/02/2012 ⁽¹⁾		S		600 D \$ 6.68	1,091,858	D
Common Stock	04/02/2012 ⁽¹⁾		S		900 D \$ 6.69	1,090,958	D
Common Stock	04/02/2012 ⁽¹⁾		S		3,400 D \$ 6.7	1,087,558	D

Edgar Filing: STARR CHRISTOPHER M - Form 4

Common Stock	04/02/2012 ⁽¹⁾	S	400	D	\$ 6.71	1,087,158	D
Common Stock	04/02/2012 ⁽¹⁾	S	800	D	\$ 6.72	1,086,358	D
Common Stock	04/02/2012 ⁽¹⁾	S	500	D	\$ 6.73	1,085,858	D
Common Stock	04/02/2012 ⁽¹⁾	S	500	D	\$ 6.74	1,085,358	D
Common Stock	04/02/2012 ⁽¹⁾	S	100	D	\$ 6.75	1,085,258	D
Common Stock	04/02/2012 ⁽¹⁾	S	100	D	\$ 6.7525	1,085,158	D
Common Stock	04/02/2012 ⁽¹⁾	S	600	D	\$ 6.77	1,084,558	D
Common Stock	04/02/2012 ⁽¹⁾	S	1,200	D	\$ 6.78	1,083,358	D
Common Stock	04/02/2012 ⁽¹⁾	S	185	D	\$ 6.79	1,083,173	D
Common Stock	04/02/2012 ⁽¹⁾	S	200	D	\$ 6.795	1,082,973	D
Common Stock	04/02/2012 ⁽¹⁾	S	200	D	\$ 6.8	1,082,773	D
Common Stock	04/02/2012 ⁽¹⁾	S	100	D	\$ 6.82	1,082,673	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V	(A)	(D)

Stock options (right to buy) \$ 2.83 04/02/2012⁽¹⁾ M 10,085 11/26/2006⁽²⁾ 05/26/2016 Common Stock 10,085

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
STARR CHRISTOPHER M C/O RAPTOR PHARMACEUTICAL CORP. 9 COMMERCIAL BLVD., SUITE 200 NOVATO, CA 94949	X		Chief Executive Officer	

Signatures

/s/ Kim R. Tsuchimoto, CFO, Raptor Pharmaceutical Corp.,
Attorney-in-fact 04/04/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2012.
- (2) Original option grant vests 6/36ths on May 26, 2006 and 1/36th per month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.